A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT05952869, this PHASE3 trial focuses on Familial Hypercholesterolemia and Hypercholesterolemia and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 16 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 11 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Barranquilla, Colombia , Boca Raton, United States , Bodø, Norway , Bogotá, Colombia , Brno, Czechia , Budapest, Hungary , Camperdown, Australia , Chicoutimi, Canada , Christchurch, New Zealand and 43 more locations